Is Venus Remedies overvalued or undervalued?

As of 28 May 2025, the valuation grade for Venus Remedies moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios supporting this assessment include a PE ratio of 15.32, an EV to EBITDA of 6.49, and a PEG ratio of 0.48, all of which suggest that the stock is trading at a lower valuation compared to its earnings growth potential.
In comparison to its peers, Venus Remedies stands out favorably against Sun Pharma, which has a PE ratio of 35.25, and Divi's Lab, with a PE ratio of 79.33, both categorized as expensive. Other attractive peers include Cipla at a PE of 22.99 and Dr. Reddy's Labs at 19.49, further reinforcing the undervaluation of Venus Remedies. Notably, the company's stock has outperformed the Sensex significantly over the past five years, with a return of 704.41% compared to the Sensex's 143.05%, highlighting its strong market performance relative to broader market trends.